Shattuck Labs, Inc. STTK

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
40/100
Developing

About Shattuck Labs, Inc.

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific … Full STTK analysis →

Competitive advantage assessment

Key strengths

  • Operating Leverage in Effect Operating leverage is evident (score 0.82), with margins expanding over time.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.83), providing operational cushion.

Key risks

  • Below-Peer Operating Efficiency Operating margin at 22.9th percentile indicates below-peer efficiency.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.22), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
29

Where STTK ranks in Biotechnology

Shattuck Labs, Inc. ranks #366 of 713 scored companies in Biotechnology by moat score — the top 51%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near STTK in Biotechnology
# Company Moat score Rating
362 Rallybio Corporation RLYB 41/100 Developing
363 Upstream Bio, Inc. UPB 41/100 Developing
364 Coherus BioSciences, Inc. CHRS 41/100 Developing
365 ProMIS Neurosciences Inc. PMN 41/100 Developing
366 Shattuck Labs, Inc. STTK 40/100 Developing
367 BeyondSpring, Inc. BYSI 40/100 Developing
368 Oncternal Therapeutics, Inc. ONCT 40/100 Developing
369 Belite Bio, Inc BLTE 40/100 Developing
370 uniQure N.V. QURE 40/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How STTK scores on the Corporate Default defenses

Pricing Power

Score 29 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 20 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 30 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 40 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 55 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 69 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding STTK's moat

What is Shattuck Labs, Inc.'s moat score?

Shattuck Labs, Inc. (STTK) scores 40 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #366 of 713 scored companies in Biotechnology, the top 51%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (69/100) and its weakest is Cost Advantage (20/100).

How does Shattuck Labs, Inc. compare with other Biotechnology companies?

Shattuck Labs, Inc. ranks #366 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are ProMIS Neurosciences Inc. (PMN) at 40 just above it and BeyondSpring, Inc. (BYSI) at 40 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Shattuck Labs, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Shattuck Labs, Inc.?

The Corporate Default template measures 6 defenses, and STTK scores: Pricing Power (29), Cost Advantage (20), Customer Stickiness (30), Capital Efficiency (40), Resilience (55), Scale & Market Position (69). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000